24/7 Market News – (NASDAQ: DBTX) shares are poised to gain as they report top line data from Phase 1 trial.

Shares are at bid at $2.55 and do not trade much for premarket. The stocks highest volume day was in 2021 with only 4 million shares traded.  The stock has drifted down over the past year on light volume.  

Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy

https://www.globenewswire.com/news-release/2022/06/28/2470202/0/en/Decibel-Therapeutics-Reports-Positive-Data-from-Interim-Analysis-of-Ongoing-Phase-1b-Clinical-Trial-of-DB-020-in-Patients-Receiving-Cisplatin-Chemotherapy.html